Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 450-455

  Gallet, Romain ^a   Ternacle, Julien ^a   Damy, Thibaud ^a   Guendouz, Soulef ^a   Bremont, Camille ^a   Seemann, Aurélien ^a   Gueret, Pascal ^a   Dubois Rande, Jean Luc ^a   Lim, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cardiogenic shock; Dobutamine; Heart failure; Ivabradine; Oxygen consumption

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; IVABRADINE; LOOP DIURETIC AGENT; OXYGEN; BENZAZEPINE DERIVATIVE; CARDIOTONIC AGENT;

ADULT; ARTICLE; BRADYCARDIA; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIASTOLE; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART VENTRICLE FILLING; HUMAN; MALE; MIDDLE AGED; MORTALITY; OXYGEN CONSUMPTION; PILOT STUDY; PROSPECTIVE STUDY; REST; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; URINE VOLUME; AGED; DRUG COMBINATION; DRUG EFFECTS; HEART FAILURE, SYSTOLIC; HEMODYNAMICS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; BENZAZEPINES; CARDIOTONIC AGENTS; DOBUTAMINE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, SYSTOLIC; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922404579     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.093     Document Type: Article

References (33)

1. Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation 2008; 117: 686-97.
2. Topalian S, Ginsberg F, Parrillo JE. Cardiogenic shock. Crit CareMed 2008; 36: S66-74.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
4. Chiolero R, Flatt JP, Revelly JP, Jequier E. Effects of catecholamines on oxygen consumption and oxygen delivery in critically ill patients. Chest 1991; 100: 1676-84.
5. De Backer D,Moraine JJ, Berre J, Kahn RJ, Vincent JL. Effects of dobutamine on oxygen consumption in septic patients. Direct versus indirect determinations. Am J Respir Crit Care Med 1994; 150: 95-100.
6. Kulka PJ, Tryba M. Inotropic support of the critically ill patient. A review of the agents. Drugs 1993; 45: 654-67.
7. Teboul JL, Graini L, Boujdaria R, Berton C, Richard C. Cardiac index vs oxygen-derived parameters for rational use of dobutamine in patients with congestive heart failure. Chest 1993; 103: 81-5.
8. Tisdale JE, Patel R,Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38: 167-80.
9. Al Bannay R, Bohm M, Husain A. Heart rate differentiates urgency and emergency in hypertensive crisis. Clin Res Cardiol 2013; 102: 593-8.
10. Hoke RS, Muller-Werdan U, Lautenschlager C, Werdan K, Ebelt H. Heart rate as an independent risk factor in patients with multiple organ dysfunction: A prospective, observational study. Clin Res Cardiol 2012; 101: 139-47.
11. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.
12. Roubille F, Tardif JC. New therapeutic targets in cardiology: Heart failure and arrhythmia: HCN channels. Circulation 2013; 127: 1986-96.
13. Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
14. Link A, Reil JC, Selejan S, Bohm M. Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol 2009; 98: 513-5.
15. Roubille F, Lattuca B, Busseuil D, et al. Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment? Med Hypotheses 2013; 81: 202-6.
16. Zwicker C, Becker M, Lepper W, Koch KC, Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: Successful treatment with ivabradine. Cardiology 2010; 116: 174-7.
17. Ihlen H, Amlie JP, Dale J, et al. Determination of cardiac output by Doppler echocardiography. Br Heart J 1984; 51: 54-60.
18. Christie J, Sheldahl LM, Tristani FE, Sagar KB, Ptacin MJ, Wann S. Determination of stroke volume and cardiac output during exercise: Comparison of two-dimensional and Doppler echocardiography, Fick oximetry, and thermodilution. Circulation 1987; 76: 539-47.
19. Huntsman LL, Stewart DK, Barnes SR, Franklin SB, Colocousis JS, Hessel EA. Noninvasive Doppler determination of cardiac output in man. Clinical validation. Circ 1983; 67: 593-602.
20. Hu K, Liu D, Niemann M, et al. Methods for assessment of left ventricular systolic function in technically difficult patients with poor imaging quality. J Am Soc Echocardiogr 2013; 26: 105-13.
21. Gallet R, Lellouche N, Mitchell-Heggs L, et al. Prognosis value of central venous oxygen saturation in acute decompensated heart failure. Arch Cardiovasc Dis 2012; 105: 5-12.
22. Hettrick DA, Pagel PS, Lowe D, Tessmer JP, Warltier DC. Increases in inotropic state without change in heart rate: Combined use of dobutamine and zatebradine in conscious dogs. Eur J Pharmacol 1996; 316: 237-44.
23. Wynsen JC, O'Brien PD, Warltier DC. Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium. J Am Coll Cardiol 1994; 23: 233-41.
24. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008; 10: 550-5.
25. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-85.
26. Borer JS, Bohm M, Ford I, et al. Efficacy and safety of ivabradine in patientswith severe chronic systolic heart failure (from the SHIFT study). AmJ Cardiol 2014; 113: 497-503.
27. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34: 2263-70.
28. Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-85.
29. Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-15.
30. Tan LB, Schlosshan D, Hall AS. Cardiac functional benefits of ivabradine therapy in patients with severe heart failure. Int J Cardiol 2013; 165: 389-90.
31. Lim P, Yanulis GE, Verhaert D, et al. Coupled pacing improves left ventricular function during simulated atrial fibrillation withoutmechanical dyssynchrony. Europace 2010; 12: 430-6.
32. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA 2005; 294: 1625-33.
33. Nuding S, Ebelt H, Hoke RS, et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol 2011; 100: 915-23.